GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (MIL:1EW) » Definitions » Cyclically Adjusted PS Ratio

Edwards Lifesciences (MIL:1EW) Cyclically Adjusted PS Ratio : 8.80 (As of Jun. 02, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Edwards Lifesciences Cyclically Adjusted PS Ratio?

As of today (2025-06-02), Edwards Lifesciences's current share price is €62.01. Edwards Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €7.05. Edwards Lifesciences's Cyclically Adjusted PS Ratio for today is 8.80.

The historical rank and industry rank for Edwards Lifesciences's Cyclically Adjusted PS Ratio or its related term are showing as below:

MIL:1EW' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 8.13   Med: 13.33   Max: 23.68
Current: 9.84

During the past years, Edwards Lifesciences's highest Cyclically Adjusted PS Ratio was 23.68. The lowest was 8.13. And the median was 13.33.

MIL:1EW's Cyclically Adjusted PS Ratio is ranked worse than
86.96% of 483 companies
in the Medical Devices & Instruments industry
Industry Median: 2.19 vs MIL:1EW: 9.84

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Edwards Lifesciences's adjusted revenue per share data for the three months ended in Mar. 2025 was €2.223. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €7.05 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Edwards Lifesciences Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Edwards Lifesciences's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences Cyclically Adjusted PS Ratio Chart

Edwards Lifesciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.16 22.91 11.66 10.76 9.58

Edwards Lifesciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.04 12.34 8.67 9.58 9.12

Competitive Comparison of Edwards Lifesciences's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, Edwards Lifesciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Cyclically Adjusted PS Ratio falls into.


;
;

Edwards Lifesciences Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Edwards Lifesciences's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=62.01/7.05
=8.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Edwards Lifesciences's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.223/134.9266*134.9266
=2.223

Current CPI (Mar. 2025) = 134.9266.

Edwards Lifesciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.833 100.684 1.116
201509 0.831 100.392 1.117
201512 0.930 99.792 1.257
201603 0.958 100.470 1.287
201606 1.037 101.688 1.376
201609 1.007 101.861 1.334
201612 1.112 101.863 1.473
201703 1.272 102.862 1.669
201706 1.158 103.349 1.512
201709 1.063 104.136 1.377
201712 1.162 104.011 1.507
201803 1.125 105.290 1.442
201806 1.258 106.317 1.597
201809 1.215 106.507 1.539
201812 1.350 105.998 1.718
201903 1.380 107.251 1.736
201906 1.512 108.070 1.888
201909 1.561 108.329 1.944
201912 1.657 108.420 2.062
202003 1.608 108.902 1.992
202006 1.324 108.767 1.642
202009 1.535 109.815 1.886
202012 1.528 109.897 1.876
202103 1.619 111.754 1.955
202106 1.813 114.631 2.134
202109 1.763 115.734 2.055
202112 1.863 117.630 2.137
202203 1.935 121.301 2.152
202206 2.074 125.017 2.238
202209 2.133 125.227 2.298
202212 0.659 125.222 0.710
202303 2.232 127.348 2.365
202306 1.959 128.729 2.053
202309 1.912 129.860 1.987
202312 1.913 129.419 1.994
202403 2.025 131.776 2.073
202406 2.131 132.554 2.169
202409 2.040 133.029 2.069
202412 2.241 133.157 2.271
202503 2.223 134.927 2.223

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Edwards Lifesciences  (MIL:1EW) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Edwards Lifesciences Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Edwards Lifesciences Business Description

Address
One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Edwards Lifesciences Headlines

No Headlines